Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sandeep Sisodiya has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Differential roles of SALL transcription factors in breast cancer: Potential biomarkers

    by Sandeep Sisodiya, Payal Singh, Tannu Joshi, Asiya Khan, Neetu Mishra, Sandeep Kumar, Pranay Tanwar, Usha Agrawal, Showket Hussain


  • Levonorgestrel-induced modulation of triple negative breast cancer proliferation via glucocorticoid receptor

    by Banashree Bondhopadhyay, Navya Aggarwal, Mukesh Chourasia, Sandeep Sisodiya, Showket Hussain

    Indiscriminate use of levonorgestrel, a progestin-only contraceptive, can affect breast cancer subtypes, as it can plausibly bind to steroid receptors other than Estrogen Receptor (ER) and Progesterone Receptor (PR). The ER, PR negative status of TNBC makes it important to explore other receptors of levonorgestrel. In this study glucocorticoid receptor (GR) was observed to show − 83.519 kcal/mol free energy of binding with levonorgestrel. To understand the effect of levonorgestrel on breast cancer cells, cellular assays were performed. In the cell proliferation assays, it was found that ER + PR + Her2- cell line, MCF-7, showed reduced proliferation upon treatment with levonorgestrel for 24 h. Whereas TNBC cell lines (MDA-MB-231 and MDA-MB-468) showed statistically significantly higher proliferation rate. Cellular adhesion assays displayed more adhesion in levonorgestrel-treated MCF-7 cells than in levonorgestrel-treated MDA-MB-231 and MDA-MB-468, as compared to the control. Ki67 (proliferation marker) showed upregulation in MCF-7 control. Levonorgestrel-treated MCF-7 cells demonstrated Ki67 downregulation. In contrast, the treatment triggered upregulation of Ki67 in TNBC cell lines on levonorgestrel treatment. Therefore, the study suggests that in the absence of ER and PR in TNBC, levonorgestrel may potentially show its effect through GR. The study emphasizes the need for further research, as there exist several factors, such as the consumption of oral contraceptive pills like levonorgestrel, which might worsen the status of breast cancer in women.


  • Open Access

    Mechanisms and Therapeutic Strategies for Endocrine Resistance in Breast Cancer: A Comprehensive Review and Meta-Analysis

    by Asiya Khan, Sandeep Sisodiya, Mehreen Aftab, Pranay Tanwar, Showket Hussain, Vivek Gupta

    Background: As per recent scenarios, drug resistance is a significant challenge in treating breast cancer for several reasons, such as genetic mutations, altered signaling pathways, and tumor microenvironment. Endocrine resistance is one of the biggest significant barriers to treatment, particularly in hormone receptor-positive (HR+) breast cancers, which depends on estrogen or progesterone signaling for growth. While therapies such as tamoxifen, aromatase inhibitors, and selective estrogen receptor degraders (SERDs) have effectively targeted these pathways, many patients develop resistance, rendering them less effective over time, which is driving a need for innovative therapeutics to treat breast cancer and overcome drug resistance and better treatment outcomes. Recent studies suggest that combining the different therapies, including immunotherapy, targeted therapy, chemotherapy, etc., with endocrine therapy, may bypass the endocrine resistance. Methodology: We conducted a comprehensive systematic review and meta-analysis examining the molecular mechanisms of endocrine resistance and evaluating randomized clinical trial outcomes, overall survival and progression-free survival in endocrine-resistant breast cancer patients treated with endocrine therapy, targeted therapy, immunotherapy, or chemotherapy. Results: We have analyzed 35 randomized clinical trial studies for different therapies along with combination therapy, and our results demonstrated that supplementary or additional therapies in endocrine resistance breast cancer patients have better progression-free and overall survival. Conclusions: The current study has demonstrated that combination therapies may have good survival results and patient outcomes in endocrine resistance. Also, This review sheds light on current challenges in drug resistance and the future direction of cancer treatment through a comprehensive analysis of these emerging treatment approaches to improve patient outcomes.


  • Open Access

    Genomic landscape of gallbladder cancer: insights from whole exome sequencing

    by Supriya Mtech Awasthi, Rahul Kumar, Dibyabhaba Pradhan, Neetu Rawal, Harsh Mtech Goel, Parameswar Msc Sahu, Sandeep Msc Sisodiya, Rashmi Rana, Sunil Kumar, Nihar Ranjan Dash, et al.

    Background: Gallbladder cancer (GBC) is a common gastrointestinal malignancy noted for its aggressive characteristics and poor prognosis, which is mostly caused by delayed detection. However, the scarcity of information regarding somatic mutations in Indian patients with GBC has hampered the development of efficient therapeutic options. In the present study, the authors attempted to bridge this gap by revealing the mutational profile of GBC. Materials and methods: To evaluate the somatic mutation profile, whole exome sequencing (WES) was performed on 66 tumor and matched blood samples from individuals with GBC. Somatic variant calling was performed using GATK pipeline. Variants were annotated at pathogenic and oncogenic levels, using ANNOVAR, VEP tools and the OncoKB database. Mutational signature analysis, oncogenic pathway analysis and cancer driver genes identification were performed at the functional level by using the maftools package. Results: Our findings focused on the eight most altered genes with pathogenic and oncogenic mutations: TP53, SMAD4, ERBB3, KRAS, ARID1A, PIK3CA, RB1, and AXIN1. Genes with pathogenic single nucleotide variations (SNVs) were enriched in oncogenic signaling pathways, particularly RTK-RAS, WNT, and TP53 pathways. Furthermore, our research related certain mutational signatures, such as cosmic 1, cosmic 6, and cosmic 18, 29, to known characteristics including patient age and tobacco smoking, providing important insights into disease etiology. Conclusions: Given the scarcity of exome-based sequencing studies focusing on the Indian population, this study represents a significant step forward in providing a framework for additional in-depth mutational analysis. Genes with substantial oncogenic and pathogenic mutations are promising candidates for developing targeted mutation panels, particularly for GBC detection.


  • Use of Immunotherapy in Gynaecological and Breast Cancer

    by Showket Hussain, Sandeep Sisodiya, Vishakha Kasherwal, Sonam Tulsyan, Asiya Khan

    Traditional drug discovery is expensive and time-consuming, which raises the question of a drug development process with shortened time and cost. Computer-aided drug designing (CADD) revolutionized the pharmaceutical industry in guiding towards the discovery of small molecules having therapeutic relevance. In recent decades, rapid evolution of rational drug discovery tools accelerates the process of CADD. CADD is categorized into structure-based drug design (SBDD) and ligand-based drug design (LBDD). SBDD requires the 3D structure of the target followed by identification of the binding site, screening of compounds and molecular docking, whereas LBDD does not require prior information about the 3D structure of the target and relies on the methods of the quantitative structure activity relationship (QSAR) and pharmacophore modelling. Toxicity prediction and optimization of lead compounds were done for their advancement against specific disease and to minimize the side effects by assessing their physiological and pharmacokinetics properties. In this chapter, the CADD steps will be discussed with emphasis on the methodologies for therapeutics development against women-associated cancer.

  • Open Access

    Exosomes: A Forthcoming Era of Breast Cancer Therapeutics

    by Banashree Bondhopadhyay, Sandeep Sisodiya, Faisal Abdulrahman Alzahrani, Muhammed A. Bakhrebah, Atul Chikara, Vishakha Kasherwal, Asiya Khan, Jyoti Rani, Sajad Ahmad Dar, Naseem Akhter, et al.

    Despite the recent advancements in therapeutics and personalized medicine, breast cancer remains one of the most lethal cancers among women. The prognostic and diagnostic aids mainly include assessment of tumor tissues with conventional methods towards better therapeutic strategies. However, current era of gene-based research may influence the treatment outcome particularly as an adjunct to diagnostics by exploring the role of non-invasive liquid biopsies or circulating markers. The characterization of tumor milieu for physiological fluids has been central to identifying the role of exosomes or small extracellular vesicles (sEVs). These exosomes provide necessary communication between tumor cells in the tumor microenvironment (TME). The manipulation of exosomes in TME may provide promising diagnostic/therapeutic strategies, particularly in triple-negative breast cancer patients. This review has described and highlighted the role of exosomes in breast carcinogenesis and how they could be used or targeted by recent immunotherapeutics to achieve promising intervention strategies.